SWOG S1900E: A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)

Objective

This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.

https://clinicaltrials.gov/ct2/show/NCT04625647

Location: Essentia Health Cancer Centers

Research Study Categories

• Adult Research Studies

Specialties

• Lung Cancer

Contact

Cancer Clinical Trials at 218-786-3308 or 844-681-7944, [email protected]